With bigger fish to fry, Eisai unloads US rights to epilepsy drug Fycompa to Catalyst

Monday, Eisai inked a deal to unload one of its smaller potatoes, epilepsy drug Fycompa (perampanel). Catalyst Pharmaceuticals will pick up its rights in the U.S. for $160 million upfront plus milestone and royalty payments tied to its future success.